Hasbro Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy LLY?
Source: Benzinga
Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, providing ratings and price targets for their stocks.
Solstice Advanced Materials: RBC Capital's Arun Viswanathan rated Solstice Advanced Materials (SOLS) as Sector Perform with a price target of $50, while shares closed at $47.49.
Ascentage Pharma Group: BTIG's Justin Zelin rated Ascentage Pharma (AAPG) as Buy with a price target of $50, with shares closing at $31.73.
Super League Enterprise and Hasbro: Aegis Capital rated Super League Enterprise (SLE) as Buy with a price target of $5, and Seaport Global rated Hasbro (HAS) as Buy with a price target of $100, with respective closing prices of $1.18 and $76.70.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 878.240
Low
950.00
Averages
1192
High
1500
Current: 878.240
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
Eli Lilly Acquires Centessa Pharmaceuticals to Enhance Neuroscience Portfolio
- Acquisition Overview: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for $38 per share in cash, valuing the transaction at approximately $6.3 billion, with a contingent value right (CVR) potentially raising the total consideration to $47 per share, indicating strong confidence in Centessa.
- Strategic Expansion: This acquisition aims to enhance Lilly's market presence in neuroscience and sleep disorder treatments, particularly targeting experimental therapies for excessive daytime sleepiness and related neurological conditions, thereby diversifying its product pipeline.
- Positive Market Reaction: Following the announcement, Centessa Pharmaceuticals' stock surged over 46% in Tuesday's premarket trading, reflecting the market's favorable view of the deal and recognition of future growth potential.
- Potential Value Increase: The CVR could add approximately $1.5 billion in additional equity value to the transaction, further enhancing Centessa's attractiveness and indicating Lilly's optimistic outlook on its future research and development outcomes.
See More
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
Eli Lilly Enters Definitive Agreement to Acquire Centessa Pharmaceuticals
- Acquisition Agreement Details: Eli Lilly has entered into a definitive agreement to acquire Centessa Pharmaceuticals for $38.00 per share in cash, reflecting a strong endorsement of Centessa's promising drug pipeline.
- Potential Value Enhancement: Centessa shareholders will receive a non-transferable contingent value right that could yield an additional $9.00 per share if three specified milestones are achieved, raising the total potential value to $47.00 per share and incentivizing shareholder support for the transaction.
- Positive Market Reaction: Centessa's shares surged 47% to $40.50 in premarket trading, indicating strong market optimism regarding the acquisition and confidence in the company's drug development prospects.
- Drug Development Outlook: Centessa's lead candidate, cleminorexton, has shown best-in-class potential in clinical trials for narcolepsy, and Lilly's acquisition is expected to accelerate the commercialization of this drug, enhancing Lilly's competitive position in the neurological drug market.
See More
Trump's Tax Overhaul Saves Corporations $65 Billion
- Tax Reduction Impact: According to Bloomberg's analysis, Trump's tax overhaul has enabled major U.S. corporations to save at least $65 billion in taxes in 2025, resulting in corporate tax revenues dropping to $424 billion from $489 billion in 2024, highlighting the direct financial impact of the tax reform.
- Amazon's Tax Burden Decline: Amazon reported only $2.8 billion in federal cash income taxes for 2025, significantly lower than the over $7 billion paid in the previous two years, indicating that the new law has substantially reduced its tax burden, with expectations of continued benefits in 2026 reflecting strategic tax planning adjustments.
- Pharmaceutical Sector Gains: Despite a $13 billion increase in U.S. income, companies like Eli Lilly and AbbVie reported cash tax payments of $500 million and $3.6 billion respectively in 2025, down from previous years, demonstrating the favorable impact of the new law on the pharmaceutical industry, although some firms face potential future tax benefit losses.
- Widespread Industry Tax Cuts: Retailers such as Walmart and Home Depot, along with telecom giants like AT&T and Verizon, cited the tax reform as a reason for reduced cash tax payments in their annual filings, reflecting the broad impact of the legislation across multiple sectors, even as companies like IBM reported negative implications for future tax benefits.
See More
ELI LILLY - TALTZ AND ZEPBOUND ACHIEVE PRIMARY AND ALL IMPORTANT SECONDARY ENDPOINTS SHOWING STATISTICAL SUPERIORITY OVER TALTZ MONOTHERAPY AT 36 WEEKS
- Primary and Secondary Endpoints: The study focuses on the primary and all key secondary endpoints for statistical superiority related to Total Tz Monotherapy at 36 weeks.
- Statistical Superiority: The aim is to demonstrate that Total Tz Monotherapy is statistically superior in its effects compared to other treatments.
See More
Phase 3B Data Revealed at AAD Annual Meeting Demonstrates Enhanced Efficacy of Lilly's Taltz (Ixekizumab) Combined with Zepbound (Tirzepatide) for Adults with Psoriatic Arthritis and Obesity
New Data Presentation: Phase 3 data for the drugs IxeKizumab (brand name: Taltz) and Tirzepatide (brand name: Zepbound) was presented at an annual meeting.
Efficacy Results: The data demonstrated superior efficacy for adults suffering from psoriatic arthritis and obesity.
See More
Eli Lilly Acquires Centessa Pharmaceuticals to Enhance Neuroscience Portfolio
- Acquisition Overview: Eli Lilly has agreed to acquire Centessa Pharmaceuticals for $38 per share in cash, valuing the transaction at approximately $6.3 billion, with a contingent value right (CVR) potentially raising the total consideration to $47 per share, indicating strong confidence in Centessa.
- Strategic Expansion: This acquisition aims to enhance Lilly's market presence in neuroscience and sleep disorder treatments, particularly targeting experimental therapies for excessive daytime sleepiness and related neurological conditions, thereby diversifying its product pipeline.
- Positive Market Reaction: Following the announcement, Centessa Pharmaceuticals' stock surged over 46% in Tuesday's premarket trading, reflecting the market's favorable view of the deal and recognition of future growth potential.
- Potential Value Increase: The CVR could add approximately $1.5 billion in additional equity value to the transaction, further enhancing Centessa's attractiveness and indicating Lilly's optimistic outlook on its future research and development outcomes.
See More
Novo Nordisk Launches Wegovy Subscription Program for Obesity Treatment
- Subscription Program Launch: Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug on Tuesday, aiming to provide cash-paying patients with lower and more predictable monthly prices, thereby enhancing patient adherence to therapy.
- Pricing and Savings: The three-month subscription for the injection is priced at $329 per month, saving patients $240 annually, while the 12-month plan drops to $249 per month, allowing for savings of up to $1,200 per year, significantly easing the financial burden on patients.
- Market Competition Pressure: As Novo's Wegovy drug experiences rapid uptake in the U.S. market, it is expected to face competition from an upcoming oral GLP-1 from Eli Lilly, which currently holds about 60% of the GLP-1 market share compared to Novo's 39%.
- Patient Flexibility: Patients can opt out of the subscription while active, and Novo aims to help patients feel more comfortable managing obesity treatment in the long term, although the program is not yet available on its NovoCare platform.
See More
Eli Lilly Enters Definitive Agreement to Acquire Centessa Pharmaceuticals
- Acquisition Agreement Details: Eli Lilly has entered into a definitive agreement to acquire Centessa Pharmaceuticals for $38.00 per share in cash, reflecting a strong endorsement of Centessa's promising drug pipeline.
- Potential Value Enhancement: Centessa shareholders will receive a non-transferable contingent value right that could yield an additional $9.00 per share if three specified milestones are achieved, raising the total potential value to $47.00 per share and incentivizing shareholder support for the transaction.
- Positive Market Reaction: Centessa's shares surged 47% to $40.50 in premarket trading, indicating strong market optimism regarding the acquisition and confidence in the company's drug development prospects.
- Drug Development Outlook: Centessa's lead candidate, cleminorexton, has shown best-in-class potential in clinical trials for narcolepsy, and Lilly's acquisition is expected to accelerate the commercialization of this drug, enhancing Lilly's competitive position in the neurological drug market.
See More
Trump's Tax Overhaul Saves Corporations $65 Billion
- Tax Reduction Impact: According to Bloomberg's analysis, Trump's tax overhaul has enabled major U.S. corporations to save at least $65 billion in taxes in 2025, resulting in corporate tax revenues dropping to $424 billion from $489 billion in 2024, highlighting the direct financial impact of the tax reform.
- Amazon's Tax Burden Decline: Amazon reported only $2.8 billion in federal cash income taxes for 2025, significantly lower than the over $7 billion paid in the previous two years, indicating that the new law has substantially reduced its tax burden, with expectations of continued benefits in 2026 reflecting strategic tax planning adjustments.
- Pharmaceutical Sector Gains: Despite a $13 billion increase in U.S. income, companies like Eli Lilly and AbbVie reported cash tax payments of $500 million and $3.6 billion respectively in 2025, down from previous years, demonstrating the favorable impact of the new law on the pharmaceutical industry, although some firms face potential future tax benefit losses.
- Widespread Industry Tax Cuts: Retailers such as Walmart and Home Depot, along with telecom giants like AT&T and Verizon, cited the tax reform as a reason for reduced cash tax payments in their annual filings, reflecting the broad impact of the legislation across multiple sectors, even as companies like IBM reported negative implications for future tax benefits.
See More
